Showing 361-370 of 1478 results for "".
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac
- New from BTL: Meet The EMSCULPT NEO Edge Applicator for the Lateral Abdomenhttps://practicaldermatology.com/news/new-from-btl-meet-the-emsculpt-neo-edge-applicator-for-the-lateral-abdomen/2461265/BTL is launching the new Edge Applicators to treat the entire lateral abdomen. Shipping will begin in S
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation
- Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/sirnaomics-doses-first-patient-in-phase-2b-study-of-stp705-for-treatment-of-squamous-cell-skin-cancer/2460857/Sirnaomics, Inc. dosed the first patient in a Phase 2b study of the company's drug candidate, STP705, for the trea
- Acne News: Clascoterone Cream 1% Exhibits Long-Term Safety for Treatment of Acnehttps://practicaldermatology.com/news/acne-news-clascoterone-cream-1-exhibits-long-term-safety-for-treatment-of-acne/2460442/Cassiopea SpA’s Clascoterone cream 1% is safe for the treatment of acne with low rates of treatment-related adverse events, according to a study in the online issue of
- Pfizer's Abrocitinib Improves Atopic Dermatitis in Phase 3 Studyhttps://practicaldermatology.com/news/pfizers-abrocitinib-improves-atopic-dermatitis-in-phase-3-study/2460316/Top-line Results from a third Phase 3 trial of Pfizer's abrocitinib for moderate to severe atopic dermatitis showed improvements in skin
- Alastin’s TransFORM Body Treatment May Enhance Cryolipolyis Outcomeshttps://practicaldermatology.com/news/alastins-transform-body-treatment-may-enhance-cryolipolyis-outcomes/2459996/Alastin’s TransFORM Body Treatment with TriHex Technology may accelerate outcomes seen with cryolipolysis, according to new research in the Journal of Drugs in Dermatology.
- Melanoma Reduces Alzheimer's Risk: Studyhttps://practicaldermatology.com/news/melanoma-reduces-alzheimers-risk-study/2457794/Individuals diagnosed with malignant melanoma may have a reduced risk of developing Alzheimer's disease. New findings, recently published online in
- EpigenCare Named as Johnson & Johnson Innovation Finalist in Skincare Challengehttps://practicaldermatology.com/news/epigencare-named-as-johnson-johnson-innovation-finalist-in-skincare-challenge/2457829/EpigenCare Inc., a personalized skincare startup company, is a finalist in Johnson & Johnson Innovation’s Digital Beauty Quickfire Challenge. The Challenge